

PUBLIC HEALTH INSTITUTE OSTRAVA Center of Clinical Laboratories Location nr. 1 - Ostrava Laboratory for mycobacterial diagnostics

Partyzánské náměstí 2633/7, Moravská Ostrava, 702 00 Ostrava





VAT: CZ71009396

Testing protocol n. 20/2021/SMU

EN 14 348 Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of mycobactericidal activity of chemical disinfectants in the medical area including instrument disinfectants. Test methods and requirements (phase 2/ step 1)

Customer:

SCHÜLKE CZ s r.o. Lidická 445

735 81 Bohumín IČ 24301779

Order nr.: 020-2021-10-22 Date of the order: 12.10.2021

Reference number: ZU/10564/2021

Sample identification:

Name of the product i:

Batch number i:

Expiration date :: Expiration date i:

Manufacturer i:

Storage conditions i:

Product diluent recommended by the manufacturer i:

Active substance(s) and concentration(s) i: 75 g sodium dichlorisokyanurate - dihydrate (1 tbl. approx. 1,5 g of active chlorine)

Supportive substance(s) and concentration(s) i:

Product type i:

Appearance and composition:

Date of delivery:

Dates of testing:

i - data provided by customer

chloramix® dt

604555

01/2024

not mentioned Schülke CZ s r.o.

room temperature, dark

hard water

Biocide

White crystalline tablets (tbl.)

27.10.2021

31. 10. 2021, 14. 11. 2021

Testing protocol n. 20/2021/SMU

EN 14 348 Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of mycobactericidal activity of chemical disinfectants in the medical area including instrument disinfectants. Test methods and requirements (phase 2/ step 1)

Results (see annexes for details):

For the reference strain *Mycobacterium terrae DSM 43227*, a reduction of> 4 log orders were achieved at a product concentration of 1 tbl. / 1 l at 15 and 30 minutes; 1 tbl. / 1.5 l at 15, 30 and 60 minutes and 1 tablet. / 3 l in 15 minutes.

For the reference strain *Mycobacterium avium DSM 44157*, a reduction of> 4 log orders of magnitude were achieved at a product concentration of 1 tbl. / 1 l at 15 and 30 minutes; 1 tbl. / 1.5 l at 15, 30 and 60 minutes and 1 tablet. / 3 l in 15 minutes.

Special notes regarding results: All controls and validations were within limits. No precipitates or turbidity were observed during the test procedure.

Conclusion:

According to **EN 14348** product batch number **604555** chloramix® dt in a concentration of **1 tablet per 3l** of water shows **mycobactericidal** activity within **15 minutes**, at 20 ° C, under conditions of **high organic load** (bovine albumin 3 g / l + 3 ml erythrocytes) for reference strains **Mycobacterium avium** and **Mycobacterium terrae**. The mean reduction in six replicates with the **Mycobacterium avium** as a limit organism was **5.131** \pm **0.04**^{a)} of logarithmic orders. The second test microorganism was tested once and showed a higher reduction compared to **Mycobacterium avium**.

Ziromini ústav sa sídkala v Ontasší
Centrum klinických laboratori
Oddělení hakteriologie a mykologie
Laboratoř pro diagnostiku mykobakterií
Partyzánské náměstí 2633/7
Moravská Ostrava 702 00 Ostrava
Tulefon: 596 200 220

In Ostrava: 15th December 2021

Authorized by: Mgr. Vít Ulmann
Head of the Laboratory

No part of this report may be reproduced in any form without the written permission of the testing laboratory. The test results relate only to the test sample as received. The laboratory is not responsible for the data provided by the customer. Centre of Clinical Laboratories - Testing Laboratory No. 1554 accredited by ČIA according to ČSN EN ISO/IEC 17025: 2018. The list of methods within the scope of accreditation is available at www.zuova.cz.The sample was examined according to SOP No. 4016.

20/2021/SMU

Page 2/5

Protocol attachment Nr. 1: 20/2021/SMU

EN **14348** Product name: **chloramix® dt** Batch no .: **604555**, Manufacturer: Schülke CZ s r.o .; Storage conditions (temperature and others): room temperature, darkness; Number of plates spread 2 ml; Neutralizing agent: Polysorbate 80–30 g / l, Sodium thiosulphate (Na2S2O3) - 5 g / l, L-histidine - 1 g / l. Wash solution: Saline peptone solution Test temperature: 20 ° C. Interfering substances: High load - Bovine albumin 3 g / l + 3 ml (BA) erythrocytes (ERY); Test organism: *Mycobacterium terrae* DSM 43227, Incubation temperature 36 ° C Date of the test: **31**st **October 2021**

Elaborated by: Vít Ulmann Responsible person: Vít Ulmann

Signature:

<u>Contro</u>	<u>ls and</u>	valid	ations:

Validation suspension (N _{vo})		Experimental conditions control (A)		Neutralizer control (B)			Validation (product control) (C)				
V _{c1}	100	V-100 F	V _{c1}	72	X=71	V _{c1}	90 /		V _{c1}	52	,
V _{c2}	101	X=100,5	V _{c2}	70		V _{c2}	91	X=90,5	V _{c2}	61	X=56,5
39 ≤ x from Nv ₀ ≤ 160? X z A ≥ 0.5 * x from N YES \boxtimes NO YES \boxtimes NO		٠.	X z B ≥ 0. 5 * x from Nv _{0?} YES ⊠ NO		X z C ≥ 0. 5 * x from Nv _{0?} YES ⊠ NO		٠.				

Test suspension and test:

Test suspension control (N a N ₀)	N 10 ⁻⁷	V _{c1} (128+132) 260	V _{c2} (141+112) 253	$X_{wm} = 317.72 \times 10^7 = log = 9.50$ $N_0 = N/10 = lg 8.50$ $8.17 \le N_0 \le 8.70$? YES ? NO
	10-8	(35+58) 93	(52+41) 93	

Concentration of the product (dilution)	Dilution step	V _{c1}	V _{c2}	Lg N _a = lg (x x 10 or x _{wm} x 10)	Lg R (N ₀ = lg 8.50)	Exposure time
	10°	<14*	<14*			
1 461 /11	10-1	<14	<14			
1 tbl. /1 l	10-2	<14	<14	2.15	6.36	15 min
	10-3	<14	<14		4	
	100	<14*	<14*			
1 tbl. /1 l	10-1	<14	<14			
1 (0). /11	10-2	<14	<14	2.15	6.36	30 min
	10 ⁻³	<14	<14	~	1.1	
	10°	<14*	<14*			
1 tbl. /1.5 l	10-1	<14	<14			4
1 (0). /1.5 (10-2	<14	<14	2.15	6.36	15 min
	10 ⁻³	<14	<14	1		
	10°	<14*	<14*		6.36	
1 tbl. /1.5 l	10-1	<14	<14	1		
1 101. / 1.5 1	10-2	<14	<14	2.15		30 min
	10 ⁻³	<14	<14			
	10°	<14*	<14*			
1 tbl. /1.5 l	10-1	<14	<14	9.45		
1 (01. / 1.5)	10-2	<14	<14	2.15	6.36	60 min
	10 ⁻³	<14	<14			1 1 1 1 1 1
	10°	171*(86+85)	186*(98+88)			
1 tbl. /3 l	10-1	<14	<14	2.25		4= .
T (DI. / 3 I	10-2	<14	<14	3.25	5.25	15 min
	10-3	<14	<14			

No part of this report may be reproduced in any form without the written permission of the testing laboratory. The test results relate only to the test sample as received. The laboratory is not responsible for the data provided by the customer. Centre of Clinical Laboratories - Testing Laboratory No. 1554 accredited by ČIA according to ČSN EN ISO/IEC 17025: 2018. The list of methods within the scope of accreditation is available at www.zuova.cz.The sample was examined according to SOP No. 4016.

20/2021/SMU

Page 3/5

Protocol attachment Nr. 2: 20/2021/SMU

EN **14348** Product name: **chloramix**® **dt** Batch no.: **604555** Manufacturer: Schülke CZ s r.o.; Storage conditions (temperature and others): room temperature. darkness; Number of plates spread 2 ml. Neutralizing agent: Polysorbate 80-30 g / l. Sodium thiosulphate (Na2S2O3) - 5 g / l. L-histidine - 1 g / l; Wash solution: Saline peptone solution Test temperature: 20 ° C Interfering substances: High load - Bovine albumin 3 g / l + 3 ml (BA) erythrocytes (ERY); Test organism: *Mycobacterium avium* DSM 44157; Incubation temperature 36 ° C Date of the test: **31**st **October 2021**

Elaborated by: Vít Ulmann Responsible person: Vít Ulmann

Signature:

Contro	ls and	valid	ations:

		Experim- control	perimental conditions ntrol (A)		Neutralizer control (B)		Validation (product control) (C)				
V _{c1}	82	V-02	V _{c1}	65	X=64	V _{c1}	50		V _{c1}	46	
V _{c2}	84	X=83	V _{c2}	63		V _{c2}	60	X=55	V _{c2}	39	X=42,5
	39 ≤ x from Nv ₀ ≤ 160? $X z A \ge 0.5 * x$ from Nv _{0?} YES \boxtimes NO YES \boxtimes NO		X z B ≥ 0. 5 * x from Nv _{0?} YES ⊠ NO		X z C ≥ 0. 5 * x from Nv _{0?} YES ⊠ NO						

Test suspension and test:

Test suspension control	N	V _{c1}	V _{c2}	$X_{wm} = 273.63 \times 10^7 = \log = 9.44$
(N a N0)	10-7	(112+118)	(121+114)	N ₀ = N/10 = Ig 8.44
		230	235	8.17 ≤ N _o ≤ 8.70? YES ⊠ NO
	10-8	(63+69)	(81+76)	
		132	157	1

Concentration of the product (dilution)	Dilution step	V _{c1}	V _{c2}	Lg N _a = lg (x x 10 or x _{wm} x 10)	<u>Lg R</u> (N ₀ = lg 8.44)	Exposure time
	10°	<14*	<14*			
1 461 /41	10-1	<14	<14			
1 tbl. /1 l	10-2	<14	<14	2.15	6.29	15 min
	10-3	<14	<14	1		
	10°	<14*	<14*			
1 tbl. /1 l	10-1	<14	<14	2.45		20 :
1 (0). /11	10-2	<14	<14	2.15	6.29	30 min
	10 ⁻³	<14	<14			
	10°	<14*	<14*	1		
1 tbl. /1.5 l	10-1	<14	<14			4= .
1 (01. / 1.5)	10-2	<14	<14	2.15	6.29	15 min
	10-3	<14	<14			
	10°	<14	<14			
1 tbl. /1.5 l	10-1	<14	<14	2.15		
1 (01. / 1.5)	10-2	<14	<14	2.15	6.29	30 min
	10-3	<14	<14			
	10°	<14	<14			
1 tbl. /1.5 l	10-1	<14	<14	2.45		
T (DI. / 1.5 I	10-2	<14	<14	2.15	6.29	60 min
	10-3	<14	<14			
	10°	190*(89+101)	197*(92+105)			
1 tbl. /3 l	10-1	<14	<14	2.20	- 4-++	45
T (DI. / 5)	10-2	<14	<14	3.29 5.15**	5.15**	15 min
	10 ⁻³	<14	<14			

No part of this report may be reproduced in any form without the written permission of the testing laboratory. The test results relate only to the test sample as received. The laboratory is not responsible for the data provided by the customer. Centre of Clinical Laboratories - Testing Laboratory No. 1554 according to ČSN EN ISO/IEC 17025: 2018. The list of methods within the scope of accreditation is available at www.zuova.cz.The sample was examined according to SOP No. 4016.

20/2021/SMU

Page 4 / 5

Protocol attachment Nr. 3: 20/2021/SMU

EN 14348 Product name: chloramix® dt Batch no.: 604555; Manufacturer: Schülke CZ s r.o.; Storage conditions (temperature and others): room temperature. dark. Number of spread plates 2 ml; Neutralizing agent: Polysorbate 80-30 g / I. Sodium thiosulphate (Na2S2O3) - 5 g / I. L-histidine - 1 g / I; Wash solution: Saline peptone solution; Test temperature: 20 ° C; Interfering substances: High load - Bovine albumin 3 g / I (BA) + 3 ml erythrocytes; Test organism: Mycobacterium avium DSM 44157; Incubation temperature 36 ° C

Date of the test: 14th November 2021

Elaborated by: Vít Ulmann Responsible person: Vít Ulmann

Signature:

Repeated to	esting:
-------------	---------

Repeated testing:						
Concentration of the product (dilution)	Dilution step	V _{c1}	Vc2	Lg N _a = lg (x x 10 or x _{wm} x 10)	Lg R	Exposure time
14.11.2021	1		/	X WIII X 207	N ₀ = lg 8.44	
1 tbl. /3 l	100	235*(114+121)	229*(128+101)		140 - 18 0.44	
BA 3 g/l+ERY	10-1	<14	<14	3.32		15 min
C.	10-2	<14	<14	0.52	5.12**	
	10-3	<14	<14			
14.11.2021	2				$N_0 = \lg 8.58$	
1 tbl. /3 l	100	373*(191+182)	370*(172+198)			
BA 3 g/l+ERY	10-1	<14	<14	3.53	F 0F**	15 min
	10-2	<14	<14		5.05**	
	10-3	<14	<14		1 0	, *
14.11.2021	3				$N_0 = \lg 8.48$	
1 tbl. /3 l	10°	235*(112+123)	219*(105+114)		9	
BA 3 g/I+ERY	10-1	<14	<14	3.31	5.16**	15 min
	10-2	<14	<14		5.16**	g.
	10-3	<14	<14			
14.11.2021	4				$N_0 = \lg 8.70$	
1 tbl. /3 l	100	373*(181+192)	394*(205+189)			
BA 3 g/I+ERY	10-1	<14	<14	3.54	5.15**	15 min
	10-2	<14	<14		5.15**	
	10-3	<14	<14			
14.11.2021	5				$N_0 = lg 8.54$	
1 tbl. /3 l	100	255*(121+134)	280*(138+142)			
BA 3 g/I+ERY	10-1	<14	<14	3.39	5,15**	15 min
	10-2	<14	<14		2,12	
	10-3	<14	<14			
** The average	LOG reduction	n within six re	peats:		LOG	5,131
			-			

a) the standard deviation of the LOG reduction within six repeats = 0.03LOG

Notes: Vc1 Vc2

1 N 10⁻⁷: 231; 219 10-8:76;80 3 N 10⁻⁷: 271; 263 N= 2.75x109 Lg N= 9.44 No= 2.8x108 Lg No= 8.44

N= 3.01x109 Lg N= 9.48 No= 3.0x108 Lg No= 8.48

5 N 10⁻⁷: 298; 279 10-8:92;89

10-8:64;65

N= 3.45x109 Lg N= 9.54 No= 3.5x108 Lg No= 8.54 **2 N** 10⁻⁷: 320; 311 N= 3.79x10⁹ Lg N= 9.58

10⁻⁸: 95; 109 No= 3.8x10⁸ Lg No= 8.58 4 N 10⁻⁷: 422; 429 N= 4.96x10⁹ Lg N= 9.70

10⁻⁸: 118; 123 No= 4.9x10⁸ Lg No= 8.70

Explanatory notes: *Encountered values

 V_c = count of colonies per ml, x = average V_{c1} a V_{c2} (1. + 2) duplicate determination, X_{wm} = weighted average x. R reduction ($\lg R = \lg N_0 - \lg N_a$)

End of the protocol

No part of this report may be reproduced in any form without the written permission of the testing laboratory. The test results relate only to the test sample as received. The laboratory is not responsible for the data provided by the customer. Centre of Clinical Laboratories -Testing Laboratory No. 1554 accredited by ČIA according to ČSN EN ISO/IEC 17025: 2018. The list of methods within the scope of accreditation is available at www.zuova.cz.The sample was examined according to SOP No. 4016. 20/2021/SMU Page 5 / 5